Dr. Posadas on the Use of Circulating Tumor Cells in mCRPC

Video

In Partnership With:

Edwin M. Posadas, MD, medical director, Urologic Oncology Program, co-director, Translational Oncology Program, associate professor of medicine, Cedars-Sinai Medical Center, discusses the future of detection in metastatic castration-resistant prostate cancer (mCRPC).

Edwin M. Posadas, MD, medical director, Urologic Oncology Program, co-director, Translational Oncology Program, associate professor of medicine, Cedars-Sinai Medical Center, discusses the future of early detection in metastatic castration-resistant prostate cancer (mCRPC).

Though some medical centers will take a biopsy of the prostate every month, asking for a blood draw is less invasive. Physicians debate the use of with prostate-specific antigen (PSA) within the prostate cancer field; however, it can be useful tool for a large subset of tumors, Posadas explains.

However, there are many tumors that don’t produce PSA or have alterations that PSA does not reflect. In these cases, something like a circulating tumor assay may be complementary and add information that PSA testing may not provide. The combination has given physicians new insights into how prostate cancer behaves.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD